Optimizing Rheumatology Home Infusion Prior Auth for Biologics

The Distinct Challenges of Rheumatology Home Infusion Prior Auth

Rheumatology is a high-PA-burden specialty due to the chronic nature and cost of advanced agents like biologics and JAK inhibitors. Home infusion therapy for these medications introduces additional layers of complexity, including coordination with specialty pharmacies and navigating the medical versus pharmacy benefit split, which can vary even for the same drug depending on the mode of administration.

Key PA Triggers in Rheumatology Home Infusion

• **TNF-alpha inhibitors:** Adalimumab (Humira, biosimilars), etanercept (Enbrel), infliximab (Remicade, biosimilars), certolizumab (Cimzia), golimumab (Simponi).
• **Non-TNF biologics & targeted synthetic DMARDs:** IL-6, IL-17, IL-23 inhibitors, B-cell depletion (rituximab biosimilars), JAK inhibitors (tofacitinib, baricitinib, upadacitinib).
• **Specialty drugs for specific indications:** Anifrolumab for SLE, belimumab for SLE, ustekinumab.
• **Advanced imaging:** MRI for inflammatory arthritis assessment.
• **DEXA scans:** For osteoporosis management in chronic-steroid patients.

Navigating Payer Policies and Clinical Guidelines

Prior authorization for rheumatology home infusion therapies is heavily influenced by clinical guidelines, particularly the ACR Treatment Guidelines. Payers consistently require detailed documentation of diagnosis, disease activity, and adherence to step therapy protocols, including specific biosimilar substitution mandates. Failure to meet these criteria is a leading cause of denials, impacting patient care continuity.

Common Documentation Requirements for Home Infusion Biologics

• **Diagnosis documentation:** ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, modified New York/ASAS for AS, 2019 EULAR/ACR for SLE).
• **Disease activity assessment:** Scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
• **Prior conventional DMARD trial:** Documentation of methotrexate or sulfasalazine trial and response, or contraindication.
• **Step therapy compliance:** Evidence of failure of one or two specific TNF inhibitors, and biosimilar substitution where mandated.
• **Screening completion:** TB screening (PPD or IGRA), hepatitis B/C screening, and immunization status prior to immunosuppressive biologic initiation.

Klivira's Solution for Streamlined Rheumatology Home Infusion PA

Klivira's platform is engineered to address the unique demands of rheumatology home infusion prior authorization. By integrating directly with EMRs via SMART on FHIR and connecting to payer portals, we automate the submission of critical clinical data and manage complex payer-specific rules. This includes dynamic routing for medical (X12 278) vs. pharmacy (NCPDP SCRIPT) benefit claims and proactive management of re-authorizations.

How Klivira Addresses Rheumatology PA Complexities

• **ACR-guideline-aware policy logic:** Automated verification against clinical guidelines for step therapy sequencing and indication-specific criteria.
• **Dynamic routing for biosimilar mandates:** Handles per-payer biosimilar substitution requirements and brand-to-biosimilar conversion workflows.
• **Management of medical vs. pharmacy benefit claims:** Accurately routes claims based on administration mode and payer policy, leveraging X12 278 and NCPDP SCRIPT standards.
• **Proactive re-authorization scheduling:** Manages periodic re-authorization workflows for chronic treatments, prompting for continuous response documentation.
• **Seamless EMR integration:** Extracts necessary clinical documentation, such as disease activity scores and screening results, directly from the EMR for submission.